Coherus Oncology Inc (CHRS)

R&D Expense Growth

12.46%

Fiscal year · Period ending:

CHRS logo

CHRS R&D Expense Growth

Latest reported12.46%
CHRS FY R&D Growth (YoY) (0.00% → 12.46%)
High-resolution chart · PNG

CHRS r&d expense growth history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Coherus Oncology Inc R&D Expense Growth — Annual fiscal periods
Period endingR&D Expense Growth
12.4582%
-14.7118%
-45.1058%
-45.0963%
154.3482%
51.5681%
-14.5602%
-32.1142%
-36.1779%
19.4206%
172.3742%
150.0847%
-10.3394%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.